Biocardia Inc (BCDA) - Total Liabilities
Based on the latest financial reports, Biocardia Inc (BCDA) has total liabilities worth $3.52 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Biocardia Inc operating cash flow efficiency to assess how effectively this company generates cash.
Biocardia Inc - Total Liabilities Trend (1995–2024)
This chart illustrates how Biocardia Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Biocardia Inc to evaluate the company's liquid asset resilience ratio.
Biocardia Inc Competitors by Total Liabilities
The table below lists competitors of Biocardia Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Decent Holding Inc Ordinary Shares
NASDAQ:DXST
|
USA | $9.45 Million |
|
Acceleware Ltd
V:AXE
|
Canada | CA$6.37 Million |
|
Truscott Mining Corporation Ltd
AU:TRM
|
Australia | AU$1.79 Million |
|
Urgent.ly Inc. Common Stock
NASDAQ:ULY
|
USA | $90.10 Million |
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
Indonesia | Rp326.94 Billion |
|
NetX Holdings Bhd
KLSE:0020
|
Malaysia | RM34.86 Million |
|
Multi Ways Holdings Ltd
NYSE MKT:MWG
|
USA | $32.73 Million |
|
EMC Public Company Limited
BK:EMC
|
Thailand | ฿709.74 Million |
Liability Composition Analysis (1995–2024)
This chart breaks down Biocardia Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Biocardia Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biocardia Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biocardia Inc (1995–2024)
The table below shows the annual total liabilities of Biocardia Inc from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.89 Million | -37.10% |
| 2023-12-31 | $4.59 Million | -6.35% |
| 2022-12-31 | $4.90 Million | -8.27% |
| 2021-12-31 | $5.34 Million | +25.78% |
| 2020-12-31 | $4.25 Million | -19.97% |
| 2019-12-31 | $5.31 Million | +102.21% |
| 2018-12-31 | $2.62 Million | +8.79% |
| 2017-12-31 | $2.41 Million | +60.87% |
| 2016-12-31 | $1.50 Million | +14900.00% |
| 2015-12-31 | $10.00K | +900.00% |
| 2014-12-31 | $1.00K | -94.44% |
| 2013-12-31 | $18.00K | +50.00% |
| 2012-12-31 | $12.00K | -98.41% |
| 2011-12-31 | $756.00K | -64.94% |
| 2010-12-31 | $2.16 Million | +153.35% |
| 2009-12-31 | $851.00K | +9.52% |
| 2008-12-31 | $777.00K | +2908.25% |
| 2007-12-31 | $25.83K | -22.59% |
| 2006-12-31 | $33.37K | -95.37% |
| 2005-12-31 | $720.54K | -2.95% |
| 2004-12-31 | $742.45K | -22.93% |
| 2003-12-31 | $963.32K | +10.92% |
| 2002-12-31 | $868.49K | +10.95% |
| 2001-12-31 | $782.74K | -32.67% |
| 2000-12-31 | $1.16 Million | +16.25% |
| 1999-12-31 | $1.00 Million | +42.86% |
| 1998-12-31 | $700.00K | +16.67% |
| 1997-12-31 | $600.00K | 0.00% |
| 1996-12-31 | $600.00K | -40.64% |
| 1995-12-31 | $1.01 Million | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more